Abstract
β- D -Glucosyl-ifosfamide mustard (D 19575, glc-IPM, INN = glufosfamide) is a new agent for cancer chemotherapy. Its mode of action, which is only partly understood, was investigated at the DNA level. In the breast carcinoma cell line MCF7 glufosfamide inhibited both the synthesis of DNA and protein in a dose-dependent manner, as shown by the decreased incorporation of [3H-methyl]-thymidine into DNA and [14C]-methionine into protein of these cells. Treatment of MCF7 cells with 50 μM glufosfamide was sufficient to trigger poly(ADP-ribose) polymerase (PARP) activation, as revealed by immunofluorescence analysis. Both CHO-9 cells, which are O6-methylguanine-DNA methyltransferase (MGMT)-deficient, and an isogenic derivative, which has a high level of MGMT, showed the same cytotoxic response to β- D -glc-IPM, indicating that the O6position of guanine is not the critical target for cytotoxicity. By contrast, a sharp decrease in survival of cross-link repair deficient CL-V5 B cells was observed already at concentrations of 0.1 m Mβ- D -glc-IPM, whereas the wild-type V79 cells showed a 90% reduction in survival only after treatment with 0.5 m M of this compound. The therapeutically inactive β- L -enantiomer of glufosfamide also showed genotoxic effects in the same assays but at much higher doses. This was probably due to small amounts of ifosfamide mustard formed under the conditions of incubation. The results indicate that the DNA crosslinks are the most critical cytotoxic lesions induced by β- D -glc-IPM. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bürkle A, Chen G, Küpper J-H, Grube K and Zeller WJ (1993) Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. Carcinogenesis 14: 559–561
De Murcia G and Ménissier-de Murcia J (1994) Poly(ADP-ribose) polymerase: a molecular nick sensor. Trends Biochem Sci 19: 172–176
Dickes M (1988) Synthese und Untersuchungen zur Stabilität und biologischen Aktivität O-glykosidisch gekoppelter 2-Chlorethyl-phosphorsäurediamide – einer neuen Klasse antineoplastisch wirksamer Alkylantien. PhD thesis, University of Heidelberg
Hemminki K (1986). Reactions of Nitrogen Mustards with DNA. IARC Scientific Publication 78, pp. 55–70. IARC: Lyon
Kaina B, Fritz G, Mitra S and Coquerelle T (1991) Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) CDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 12: 1857–1867
Kawamitsu H, Hoshino H, Okada H, Miwa M and Sugimura T (1984) Monoclonal antibodies to poly(adenosine diphosphate ribose) recognize different structures. Biochemistry 23: 3771–3777
Lindahl T, Satoh MS, Poirier GG and Klungland A (1995) Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci 20: 405–411
Monks A, Scuderio DA, Johnsson DS, Paull KD and Sausville EA (1997) The NCI-anti-cancer screen: a smart screen to identify effectors of novel targets. Anti Cancer Drug Design 12: 533–541
Oei SL, Griesenbeck J and Schweiger M (1997) The role of poly ADP-ribosylation. Rev Physiol Biochem Pharmacol 131: 4135–4137
Pfuhler S and Wolf HU (1996) Detection of DNA-crosslinking agents with the alkaline comet assay. Environment Mol Mutag 27: 196–201
Pohl J, Bertram B, Hilgard P, Nowrousian MR, Stüben J and Wießler M (1995) D-19575 – a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport. Cancer Chemothe. Pharmacol 35: 364–370
Seker H, Bertram B and Wieβler M (1996) Possible role of the cytosolic β-glucosidase in the metabolism of saccharide-coupled platinum and ifosfamide mustard in tumor cells. In: ‘10th Mediterranean Congress of Chemotherapy’, Berkarda B. (ed.), pp 381–385, Monduzzi Editore
Shaw IC and Graham MI (1987) Mesna – a short review. Cancer Treatment Rev 14: 67–86
Stüben J, Port R, Bertram B, Bollow U, Hull E, Schaper M, Pohl J and Wießler M (1996) Pharmacokinetics and whole body distribution of the new chemotherapeutic agent β- D -glucosylifosfamide mustard (D 19575) and its effects on the incorporation of [3H-methyl]-thymidine in various tissues of the rat. Cancer Chemother Pharmacol 38: 355–365
Tellemann P, Overkamp WJI, van Wessel N, Studzian K, Wetselaar L, Natarajan AT and Zdienicka MZ (1995) A new complementation group of mitomycin C-hypersensitive Chinese hamster cell mutants that closely resembles the phenotype of Fanconi anemia cells. Cancer Res 55: 3412–3416
Veyhl M, Wagner K, Volk C, Gorboulev V, Baumgarten K, Weber WM, Schaper M, Bertram B, Wießler M and Koepsell H (1998) Transport of the new chemotherapeutic agent β- D -glucosyl-isophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+- D -glucose cotransporter SAAT1. Proc Natl Acad Sci USA 95: 2914–2919
Workman P (1997) Towards intelligent anticancer drug screening in the post-genome era?. Anti-Cancer Drug Design 12: 525–531
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Seker, H., Bertram, B., Bürkle, A. et al. Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent. Br J Cancer 82, 629–634 (2000). https://doi.org/10.1054/bjoc.1999.0974
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0974
Keywords
This article is cited by
-
Preclinical investigation of tolerance and antitumour activity of new fluorodeoxyglucose-coupled chlorambucil alkylating agents
Investigational New Drugs (2011)
-
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors
Cancer Chemotherapy and Pharmacology (2010)
-
Arzneimittelentwicklung: Die Reduzierung von Umweltbelastungen durch gezieltes Moleküldesign
Environmental Sciences Europe (2008)
-
Antirestenotic Effects of a Novel Polymer-Coated D-24851 Eluting Stent. Experimental Data in a Rabbit Iliac Artery Model
CardioVascular and Interventional Radiology (2007)
-
Glycolysis inhibition for anticancer treatment
Oncogene (2006)